Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 16/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506600 | 1.00 | CCR1 (0.46) | CCR1ENPP2FPR2PROKR1SPR | |
| SCHEMBL4501369 | 1.00 | CCR1 (0.46) | CCR1ENPP2FPR2PROKR1SPR | |
| SCHEMBL4511596 | 0.81 | CCR1 (0.69) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4517149 | 0.80 | CCR1 (0.59) | CCR1CYP2C19KCNH2 | |
| SCHEMBL5311863 | 0.75 | CCR1 (0.42) | CCR1FPR2PROKR1CYP2C19KCNH2 | |
| SCHEMBL4503990 | 0.68 | KDM4E (0.48) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4496602 | 0.68 | KDM4E (0.48) | CCR1CYP2C19KCNH2 | |
| SCHEMBL4496606 | 0.68 | KDM4E (0.48) | CCR1CYP2C19KCNH2 | |
| SCHEMBL27967465 | 0.68 | CYP46A1 (0.48) | KCNH2CYP46A1 | |
| SCHEMBL4634537 | 0.67 | CYP46A1 (0.50) | CYP2C19KCNH2CYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576106-B2 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576106-B2 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576106-B2 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070093467-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2007044885-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093467-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885ENPP2 876/4885FPR2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.